Search Results
IRPN: Innovation & Food & Drug Law & Policy (Sub-Topic)

93,884 Total downloads

Viewing: 1 - 50 of 697 papers

1.

Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs

Journal of Law, Medicine and Ethics, 2013, Vol. 14, No. 3: 590-610
Number of pages: 11 Posted: 20 Jun 2013 Last Revised: 11 Apr 2020
Accepted Paper Series
Rowan University School of Osteopathic Medicine, York University and Harvard Medical School
Downloads 6,997
2.

Unpatentable Drugs and the Standards of Patentability

Texas Law Review, Vol. 87, pp. 503-570, 2009
Number of pages: 68 Posted: 04 May 2008 Last Revised: 02 Jun 2013
Accepted Paper Series
affiliation not provided to SSRN
Downloads 1,890
3.

Earning Exclusivity: Generic Drug Incentives and the Hatch-Waxman Act

Antitrust Law Journal, Vol. 77, p. 947, 2011, Stanford Law and Economics Olin Working Paper No. 405, Columbia Law and Economics Working Paper No. 391
Number of pages: 44 Posted: 10 Jan 2011 Last Revised: 01 Jun 2017
Accepted Paper Series
New York University School of Law and Stanford Law School
Downloads 1,449
4.

May Your Drug Price Be Evergreen

Oxford Journal of Law and the Biosciences (2018)
Number of pages: 58 Posted: 31 Oct 2017 Last Revised: 28 Apr 2019
Accepted Paper Series
University of California Hastings Law
Downloads 1,447
5.

The Ranbaxy - Daiichi Sankyo Deal: Where Do They Go Now?

Number of pages: 21 Posted: 09 Jun 2009
Working Paper Series
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and University of Mumbai - Jamnalal Bajaj Institute of Management Studies, Mumbai
Downloads 1,381
6.

Pharmaceutical Development Phases: A Duration Analysis

FTC, Bureau of Economics Working Paper No. 274
Number of pages: 30 Posted: 25 Oct 2004
Working Paper Series
Global Economics Group, LLC, CBO and Moody's Investors Service
Downloads 1,107
7.

Spending on New Drug Development

Number of pages: 19 Posted: 15 Dec 2005 Last Revised: 08 Feb 2014
Working Paper Series
CBO and Federal Trade Commission - Bureau of Economics
Downloads 1,033
8.

Big Data and Pharmacovigilance: Using Health Information Exchanges to Revolutionize Drug Safety

99 Iowa L. Rev. 225 (2013)
Number of pages: 68 Posted: 08 Apr 2013 Last Revised: 02 May 2015
Accepted Paper Series
University of Surrey School of Law
Downloads 957
9.

Regulation of Pharmaceuticals in Canada

CANADIAN HEALTH LAW AND POLICY, 3rd ed., J. Downie, T. Caulfield & C. Flood, ed., Toronto. Butterworths, pp. 318-387, 2007
Number of pages: 56 Posted: 15 Nov 2012 Last Revised: 06 Apr 2014
Accepted Paper Series
University of Toronto - Faculty of Law and University of Manitoba - Faculty of Law (deceased)
Downloads 912
10.

How a Drug Becomes 'Ethnic': Law, Commerce, and the Production of Racial Categories in Medicine

Number of pages: 46 Posted: 12 Mar 2004
Accepted Paper Series
Northeastern University - School of Law
Downloads 906
11.

The Drug Innovation Paradox

Missouri Law Review, Forthcoming, University of Missouri School of Law Legal Studies Research Paper No. 2017-12
Number of pages: 75 Posted: 07 Apr 2017 Last Revised: 09 May 2018
Accepted Paper Series
University of Missouri School of Law
Downloads 901
12.

Drug Wars: A New Generation of Generic Pharmaceutical Delay

Harvard Journal on Legislation, Vol. 53, 2016, UC Hastings Research Paper No. 155
Number of pages: 64 Posted: 11 Sep 2015 Last Revised: 20 Jun 2016
Accepted Paper Series
University of California Hastings Law and University of California Hastings College of the Law
Downloads 798
13.

Information Policy and Genetically Modified Food: Weighing The Benefits and Costs

University of Massachusetts, Amherst Resource Economics Working Paper No. 2003-1
Number of pages: 24 Posted: 21 Apr 2003
Working Paper Series
University of Maine - Department of Resource Economics and Policy and University of Massachusetts, Amherst
Downloads 782
14.

Access to Information and the Right to Health: The Human Rights Case for Clinical Trials Transparency

American Journal of Law and Medicine, Vol. 38, pp. 63-112, 2012
Number of pages: 50 Posted: 27 Sep 2011 Last Revised: 06 Mar 2015
Accepted Paper Series
University of Toronto - Faculty of Law and Independent
Downloads 780
15.

Asymmetric Social Interactions in Physician Prescription Behavior: The Role of Opinion Leaders

Stanford University Graduate School of Business Research Paper No. 1970
Number of pages: 41 Posted: 13 Oct 2006 Last Revised: 30 Jul 2014
Working Paper Series
Stanford University - Graduate School of Business, University of Michigan, Stephen M. Ross School of Business and Rutgers, The State University of New Jersey - Rutgers Business School at Newark & New Brunswick
Downloads 775
16.

The International Regulation of Genetically Modified Organisms: Importing Caution into the U.S. Food Supply

Food and Drug Law Journal, Vol. 61, No. 2, pp. 167-196, 2006
Number of pages: 31 Posted: 18 Nov 2008 Last Revised: 28 Mar 2013
Accepted Paper Series
Fairfield University - Charles F. Dolan School of Business
Downloads 764
17.

3D-Printed Food

Minnesota Journal of Law, Science and Technology, Vol. 17, p. 855, 2016 symposium
Number of pages: 28 Posted: 03 Jan 2016 Last Revised: 23 Jul 2017
Accepted Paper Series
University of Minnesota Law School
Downloads 756
18.

An Analysis of the FDA Food Safety Modernization Act: Protection for Consumers and Boon for Business

Food and Drug Law Journal, Vol. 66, No. 3, pp. 353-376, 2011
Number of pages: 25 Posted: 10 Sep 2011
Accepted Paper Series
Fairfield University - Charles F. Dolan School of Business
Downloads 749
19.

Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health

Journal of Law, Medicine and Ethics, Forthcoming
Number of pages: 30 Posted: 28 Jun 2013 Last Revised: 24 Oct 2015
Accepted Paper Series
Carleton University - School of Public Policy and Administration
Downloads 721
20.

Two Puzzles Resolved: Of the Schumpeter - Arrow Stalemate and Pharmaceutical Innovation Markets

Iowa Law Review, Vol. 93, 2008
Number of pages: 58 Posted: 09 Apr 2007 Last Revised: 02 Jun 2013
Accepted Paper Series
Rutgers Law School
Downloads 665
21.

Patent Exclusivity versus Regulatory Exclusivity under the Hatch-Waxman Act

Indiana University Robert H. McKinney School of Law Research Paper No. 2012-30
Number of pages: 43 Posted: 04 Dec 2012 Last Revised: 19 Aug 2013
Accepted Paper Series
Penn State Dickinson Law
Downloads 659
22.

Ten Dimensions of Technology Regulation - Finding Your Bearings in the Research Space of an Emerging Discipline

DIMENSIONS OF TECHNOLOGY REGULATION, pp. 309-324, M.E.A. Goodwin et al., eds., Nijmegen: WLP, 2010 , Tilburg Law School Research Paper No. 015/2010
Number of pages: 17 Posted: 04 Jul 2010 Last Revised: 30 Mar 2013
Accepted Paper Series
Tilburg University - Tilburg Institute for Law, Technology, and Society (TILT)
Downloads 650
23.

Pharmaceutical Lemons: Innovation and Regulation in the Drug Industry

Michigan Telecommunications and Technology Law Review, Vol. 14, No. 1, pp. 1-41, 2007, University of Toronto, Legal Studies Research Paper No. 08-03
Number of pages: 42 Posted: 22 Feb 2007
Accepted Paper Series
University of Toronto - Faculty of Law
Downloads 630
24.

Food Fears: Health and Safety at the WTO

Number of pages: 42 Posted: 11 Nov 2004
Accepted Paper Series
USC Gould School of Law
Downloads 625
25.

Trade, Standards, and the Political Economy of Genetically Modified Food

Number of pages: 32 Posted: 20 Apr 2016
Working Paper Series
University of Adelaide - Centre for International Economic Studies (CIES), World Bank and World Trade Organization (WTO)

Multiple version iconThere are 2 versions of this paper

Downloads 615
26.

Foundations of EU Food Law and Policy - Ten Years of European Food Safety Authority

A. Alemanno - S. Gabbi, Foundations of EU Food Law and Policy - Ten Years of European Food Safety Authority (London: Ashgate, 2013), Forthcoming
Number of pages: 22 Posted: 11 Apr 2013
Accepted Paper Series
HEC Paris - Tax & Law
Downloads 604
27.

The Indian Pharmaceutical Industry - Fundamentals vis-a-vis Market Perception

Number of pages: 23 Posted: 08 Mar 2009
Working Paper Series
Calcutta Business School and affiliation not provided to SSRN
Downloads 556
28.

New Drug Development: Estimating Entry from Human Clinical Trials

FTC Bureau of Economics Working Paper No. 262
Number of pages: 24 Posted: 12 Sep 2003
Working Paper Series
CBO and Federal Trade Commission - Bureau of Economics
Downloads 530
29.

Accounting Profitability and the Political Process: The Case of R&D Accounting in the Pharmaceutical Industry

Number of pages: 52 Posted: 29 Nov 2014 Last Revised: 28 Jan 2020
Working Paper Series
Lancaster University - Department of Accounting and Finance, Heinrich Heine University Dusseldorf - Duesseldorf Institute for Competition Economics (DICE) and WHU - Otto Beisheim School of Management
Downloads 517
30.

Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda

Journal of Law, Medicine and Ethics, Vol. 14, No. 3, 2013, Forthcoming
Number of pages: 26 Posted: 11 Jul 2013
Accepted Paper Series
University of Texas - Pan American
Downloads 511
31.

Reverse Payment Patent Settlements in the European Union and the United States

George Mason Legal Studies Research Paper No. LS 15-22, George Mason Law & Economics Research Paper No. 15-38
Number of pages: 26 Posted: 21 Sep 2015
Accepted Paper Series
Geradin Partners, U.S. Court of Appeals for the District of Columbia Circuit and Independent
Downloads 509
32.

Food and Superfood: Organic Labeling and the Triumph of Gay Science Over Dismal and Natural Science in Agricultural Policy

Idaho Law Review, Vol. 48, p. 213. 2012, University of Louisville School of Law Legal Studies Research Paper No. 2012-07
Number of pages: 14 Posted: 03 Apr 2012 Last Revised: 14 Nov 2012
Accepted Paper Series
Michigan State University - College of Law
Downloads 464
33.

A Dose of Reality for Specialized Courts: Lessons from the VICP

University of Pennsylvania Law Review, Vol. 163, p. 1631, 2015, Stanford Public Law Working Paper No. 2623756
Number of pages: 87 Posted: 28 Jun 2015
Accepted Paper Series
Stanford Law School
Downloads 459
34.

The Hang-Up with Haccp: The Resistance to Translating Science into Food Safety Law

Food and Drug Law Journal, Vol. 58, pp. 565-594, 2003
Number of pages: 31 Posted: 29 Aug 2005
Accepted Paper Series
Institute for Food Laws & Regulations, Michigan State University
Downloads 448
35.

The Impact of Patenting on New Product Introductions in the Pharmaceutical Industry

Number of pages: 43 Posted: 07 May 2007
Working Paper Series
Georgia Institute of Technology - Scheller College of Business and University of Utah - Department of Entrepreneurship & Strategy
Downloads 442
36.

Reassessing Regulatory Compliance

Stanford Law School, Public Law and Legal Theory Working Paper No. 5
Number of pages: 60 Posted: 18 Jan 2000
Working Paper Series
Stanford Law School

Multiple version iconThere are 2 versions of this paper

Downloads 441
37.

Verify, then Trust: How to Legalize Off-Label Drug Marketing

117 Penn State Law Review 407 (2012), UGA Legal Studies Research Paper No. 2013-18
Number of pages: 37 Posted: 04 May 2013
Accepted Paper Series
University of Georgia School of Law and University of Georgia School of Law
Downloads 437
38.

Federalism in Action: FDA Regulatory Preemption in Pharmaceutical Cases in State versus Federal Courts

Brooklyn Journal of Law and Policy, Vol. 15, No. 3, 2007, NYU Law School, Public Law Research Paper No. 08-04, NYU Law and Economics Research Paper No. 08-10
Number of pages: 39 Posted: 11 Oct 2007 Last Revised: 02 Jun 2013
Accepted Paper Series
New York University School of Law
Downloads 435
39.

Matching Prescription Drugs and Consumers: The Benefits of Direct Advertising

New England Journal of Medicine, Vol. 313, pp. 513-515, August 22, 1985, Emory Public Law Research Paper No. 05-32
Number of pages: 4 Posted: 04 Oct 2005
Accepted Paper Series
Emory University - Department of Economics
Downloads 428
40.

Key Opinion Leaders and the Corruption of Medical Knowledge: What the Sunshine Act Will and Won't Cast Light On

Journal of Law, Medicine, Ethics, Vol. 14, No. 3, 2013
Number of pages: 27 Posted: 31 May 2013 Last Revised: 24 Oct 2015
Accepted Paper Series
Queen's University
Downloads 415
41.

Citizen Petitions: An Empirical Study

Cardozo Law Review, Forthcoming
Number of pages: 46 Posted: 04 Jun 2012 Last Revised: 30 Jul 2013
Accepted Paper Series
Rutgers Law School and affiliation not provided to SSRN
Downloads 412
42.

The History and Political Economy of the Hatch-Waxman Amendments

49 Seton Hall Law Review 53 (2018), University of Missouri School of Law Legal Studies Research Paper No. 2018-20
Number of pages: 76 Posted: 15 Mar 2018 Last Revised: 19 Dec 2018
Working Paper Series
University of Missouri School of Law
Downloads 410
43.

The Role of Science in Risk Regulation Under the Sps Agreement

EUI Law Working Paper No. 2006/03
Number of pages: 36 Posted: 20 Mar 2006
Working Paper Series
Kozminski University - School of Law
Downloads 410
44.

Unapproved Genetically Modified Corn: It's What's for Dinner

Iowa Law Review, Vol. 100, No. 2, 2015
Number of pages: 27 Posted: 17 Jan 2015
Accepted Paper Series
University of Iowa - College of Law
Downloads 410
45.

Leopards in the Temple: Restoring Scientific Integrity to the Commercialized Research Scene

Journal of Law, Medicine & Ethics, Vol. 32, No. 4, pp. 641-657, 2004
Number of pages: 17 Posted: 04 Apr 2005 Last Revised: 06 Apr 2014
Accepted Paper Series
University of Toronto - Faculty of Law
Downloads 384
46.

Import Safety Rules Should Not Hinder Legitimate Generic Drug Markets: The Anti-Counterfeiting Trade Agreement (ACTA)

IMPORT SAFETY: REGULATORY GOVERNANCE IN THE GLOBAL ECONOMY, Cary Coglianese, Adam Finkel, David Zaring, eds., The University of Pennsylvania Press, 2009, Boston Univ. School of Law Working Paper No. 9-25
Number of pages: 30 Posted: 25 May 2009 Last Revised: 30 Jul 2014
Accepted Paper Series
Boston University School of Law
Downloads 369
47.

Sharing R&D Risk in Healthcare via FDA Hedges

MIT Sloan Research Paper No. 5194-17
Number of pages: 51 Posted: 03 Apr 2017 Last Revised: 13 Apr 2017
Working Paper Series
Boston College - Carroll School of Management, Massachusetts Institute of Technology (MIT) - Sloan School of Management, University of Chicago, Goldman Sachs and University of Minnesota - Carlson School of Management

Multiple version iconThere are 2 versions of this paper

Downloads 368
48.

The U.S. Biologics Price Competition and Innovation Act of 2009 Triggers Public Debates, Regulatory/Policy Risks, and International Trade Concerns

Global Trade and Customs Journal, Vol. 6, No. 11 & 12, 2011
Number of pages: 34 Posted: 03 Nov 2011
Accepted Paper Series
The Kogan Law Group, P.C.
Downloads 366
49.

Playing Both Sides: Branded Sales, Generic Drugs, and Antitrust Policy

Stanford Law and Economics Olin Working Paper No. 533, 71 Hastings Law Journal 307 (2020), Rutgers Law School Research Paper
Number of pages: 52 Posted: 12 Mar 2019 Last Revised: 21 Feb 2020
Accepted Paper Series
Rutgers Law School, Stanford Law School and University of San Diego School of Law
Downloads 352
50.

From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices Through Accreditation, Certification, and Rating

Journal of Law, Medicine and Ethics, Vol. 41, No. 3, 2013
Number of pages: 10 Posted: 15 Jul 2013 Last Revised: 30 Jul 2014
Accepted Paper Series
Harvard University - Edmond J. Safra Center for Ethics
Downloads 351